Effects of Royal Jelly Administration on Lipid Profile, Satiety, Inflammation, and Antioxidant Capacity in Asymptomatic Overweight Adults

Table 4

The metabolic profile in asymptomatic subjects before and after intervention.

	TC (mmol/L)		LDL (mmol/L)		HDL (mmol/L)		TAG (mmol/L)		Glucose (mmol/L)
	Placebo	Royal jelly	Placebo	Royal jelly	Placebo	Royal jelly	Placebo	Royal jelly	Placebo	Royal jelly
Initial	5.60±1.11	5.65±1.74	3.99±1.04	3.72±1.44	1.55±0.25	1.83±0.51	1.38±0.28	1.09±0.45	5.66±0.42	5.53±0.78
Week 4	5.57±1.07	5.38±1.08	3.92±0.97	3.59±1.03	1.50±0.29	1.80±0.44	1.31±0.28	0.99±0.47	5.83±0.28	5.32±0.54
Week 8	5.58±0.81	5.27±1.29	3.92±0.76	3.55±1.23	1.47±0.28	1.77±0.42	1.39±0.44	1.01±0.50	5.60±0.48	5.22±0.55
F/U	5.56±1.02	5.21±1.70	4.05±1.24	3.49±1.07	1.42±0.29	1.75±0.39	1.40±0.38	1.02±0.67	5.58±0.56	5.25±0.56

Abbreviations. F/U: follow-up; HDL: high density lipoproteins; LDL: low density lipoproteins; TAG: triacylglycerols; TC: total cholesterol.
Values are expressed as means ± SD.
p-value denotes significant (p<0.05) difference between the change from baseline on royal jelly vs. placebo.
p-value denotes significant (p<0.05) difference as compared with the initial within group using a paired t-test.